

Supplementary Material

Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262

Leopold Kong^{1,2,3,4},
Ian A. Wilson^{2,3,4,5,*} and Peter D. Kwong^{1,*}

¹Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA.

²Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.

³International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA.

⁴Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.

⁵Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.

*Correspondence to:

Peter D. Kwong, Vaccine Research Center, Building 40, Room 4508, 40 Convent Drive, Bethesda, Maryland 20892, USA. Tel.: 1-301-594-8439; Fax: 1-301-480-2658; E-mail: pdkwong@nih.gov

Ian A. Wilson, Department of Integrative Structural and Computational Biology, BCC206, 10550 N. Torrey Pines Rd., La Jolla, California 92037, USA. Tel.: 1-858-784-9706; Fax: 1-858-784-2980; E-mail: wilson@scripps.edu

Grant Sponsor: NIH grants RO1 AI084817 (I.A.W), Scripps CHAVI-ID UM1 AI100663 (I.A.W.), GM U54 GM94586 (I.A.W.), and the Intramural Research Program of the Vaccine Research Center, NIAID/NIH.

Keywords: HIV-1 gp120, glycan shield, role of N262




Figure S1

Crystal packing of the complex of gp20 core, Fab17b and CD4. The asymmetric unit, consisting of YU2 gp120 core (grey), 17b Fab (charcoal) and two-domain CD4 (D1D2) (yellow), is shown as a molecular surface packed against neighboring symmetry mates (light brown). Glycans in the asymmetric unit are displayed as green spheres.